Cambridge, MA, United States of America

Girish Chopda

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Cambridge, MA (US) (2020)
  • Lexington, MA (US) (2022)

Company Filing History:


Years Active: 2020-2022

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Girish Chopda: Innovator in Hepatocyte Research

Introduction

Girish Chopda is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of methods for inhibiting HMGB1 expression. With a total of 2 patents, his work focuses on innovative solutions for liver-related conditions.

Latest Patents

Chopda's latest patents include compositions and methods for inhibiting HMGB1 expression. This disclosure relates to oligonucleotides, compositions, and methods useful for reducing HMGB1 expression, particularly in hepatocytes. The disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Additionally, these oligonucleotides may be designed to include targeting ligands to target specific cells or organs, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.

Career Highlights

Chopda is currently associated with Dicerna Pharmaceuticals, Inc., where he continues to advance his research in the field. His work has garnered attention for its potential impact on treating liver diseases and improving patient outcomes.

Collaborations

Some of his notable coworkers include Marc Abrams and Jihye Park, who contribute to the collaborative efforts in their research endeavors.

Conclusion

Girish Chopda's innovative work in the field of hepatocyte research and his contributions to biotechnology highlight the importance of ongoing research in medical science. His patents reflect a commitment to developing effective treatments for liver-related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…